-
1.发明申请PANTOTHENIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS 审中-公开泛酸衍生物及其在治疗微生物感染中的应用
公开(公告)号：WO2011152720A1
公开(公告)日：2011-12-08
申请号：PCT/NL2011/050384
申请日：2011-05-31
Applicant: UMC ST. RADBOUD , STICHTING KATHOLIEKE UNIVERSITEIT, RADBOUD UNIVERSITY NIJMEGEN , STICHTING KATHOLIEKE UNIVERSITEIT, RADBOUD UNIVERSITY NIJMEGEN , ZEEUWEN, Patrick Laurentius Johannes Maria , JANSEN, Patrick Antonius Martinus , SCHALKWIJK, Josephus , RUTJES, Floris Petrus Johannes Theodorus , RITZEN, Bas , HERMKENS, Pedro Harold Han
Inventor： ZEEUWEN, Patrick Laurentius Johannes Maria , JANSEN, Patrick Antonius Martinus , SCHALKWIJK, Josephus , RUTJES, Floris Petrus Johannes Theodorus , RITZEN, Bas , HERMKENS, Pedro Harold Han
IPC: A61K31/16 , A61K31/164 , A61K31/275 , A61K31/277 , A61K31/4155 , A61K31/417 , A61K31/4174 , A61K31/4178
CPC classification number: A61K45/06 , A61K31/16 , A61K31/164 , A61K31/165 , A61K31/275 , A61K31/277 , A61K31/4155 , A61K31/417 , A61K31/4174 , A61K31/4178 , Y02A50/411 , A61K2300/00
Abstract: The present invention concerns novel amides derived from pantothenic acid having antibiotic activity and novel analogues of pantetheine inhibiting the activity of pantetheinase. Combinations of such substances can suitably beused in therapeutic and or prophylactic treatment of bacterial infections, fungal and yeast infections in a human or animal subject. The present invention resides in the findingthat pantothenamidesaloneare not at antibiotically active in the presence of plasma due to the breakdown of pantothenamides by enzymes with pantetheinase activityandthat inhibition of these enzymes prevented breakdown of pantothenamides,thuspreserving their antibiotic activity under physiological conditions in mammals. The present invention thus, for the first time, makes available treatment relying on interference with microbial CoA dependent pathways and, simultaneously, inhibiting or reducing pantetheinase activity.
Abstract translation: 本发明涉及衍生自具有抗生素活性的泛酸的新型酰胺，以及泛酸胺基的新类似物抑制泛肽酶的活性。 这些物质的组合可以适当地用于人或动物受试者的细菌感染，真菌和酵母菌感染的治疗和/或预防性治疗。 本发明在于由于泛酸酰胺酶活性降低泛酸酰胺的作用而在血浆存在下不具有抗生素活性，因此这些酶的抑制可防止泛酰胺的分解，从而在哺乳动物的生理条件下保护其抗生素活性。 因此，本发明首次能够依赖于干扰微生物CoA依赖途径的治疗，同时抑制或减少泛酰胺氨基酸酶活性。
-
公开(公告)号：US20170065698A1
公开(公告)日：2017-03-09
申请号：US15354102
申请日：2016-11-17
Inventor： Hester Jeanette Bootsma , Pieter Jan Burghout , Peter Wilhelmus Maria Hermans , Johanna Jacoba Elisabeth Bijlsma , Oscar Paul Kuipers , Tomas Gerrit Kloosterman
CPC classification number: A61K39/092 , A61K9/0019 , A61K9/107 , A61K39/09 , A61K47/22 , A61K2039/54 , A61K2039/545 , A61K2039/55594
Abstract: The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also antibodies against said protein(s) are included in the invention.
Abstract translation: 本发明提供蛋白质/基因，其对于存活是必需的，因此提供了肺炎链球菌在体内的毒力，因此是针对肺炎球菌感染的疫苗制剂的理想疫苗候选物。 此外，本发明还包括针对所述蛋白质的抗体。
-
3.发明申请
公开(公告)号：WO2011152721A1
公开(公告)日：2011-12-08
申请号：PCT/NL2011/050385
申请日：2011-05-31
Applicant: UMC ST. RADBOUD , STICHTING KATHOLIEKE UNIVERSITEIT, RADBOUD UNIVERSITY NIJMEGEN , STICHTING KATHOLIEKE UNIVERSITEIT, RADBOUD , JANSEN, Patrick Antonius Martinus , SCHALKWIJK, Josephus , RUTJES, Floris Petrus Johannes Theodorus , SAUERWEIN, Robert , HERMKENS, Pedro Harold Han
Inventor： JANSEN, Patrick Antonius Martinus , SCHALKWIJK, Josephus , RUTJES, Floris Petrus Johannes Theodorus , SAUERWEIN, Robert , HERMKENS, Pedro Harold Han
IPC: A61K31/16 , A61K31/164 , A61K31/165 , A61K31/275 , A61K31/417 , A61K31/4174 , A61K31/4178 , A61K31/4155 , A61K31/277 , A61K45/06 , A61P33/06
CPC classification number: A61K45/06 , A61K31/16 , A61K31/164 , A61K31/165 , A61K31/275 , A61K31/277 , A61K31/4155 , A61K31/417 , A61K31/4174 , A61K31/4178 , Y02A50/411 , A61K2300/00
Abstract: The present invention concerns novel pantothenone compounds having pantetheinase inhibitory activity as well as antiplasmodial activity. These compounds can suitably be used in therapeutic and or prophylactic treatment of malaria. Furthermore, the present invention provides combinations of pantothenone compounds and pantothenamides. Combining a pantothenone with a pantothenamide increases the antimalarial potency by an order of magnitude. It is hypothesized that inhibition of pantetheinase activity could protect pantothenamides against degradation by serum-derived pantetheinases, thereby revealing the hitherto unknown antimalaria activity of pantothenamides. The present invention thus, for the first time, makes available compounds and combinations of compounds for use in therapeutic and or prophylactic treatment of malaria infection in a human or animal subject in need thereof, relying on interference with host or pathogen-derived pantetheinase dependent pathways.
Abstract translation: 本发明涉及具有泛肽酶抑制活性以及抗血浆活性的新型泛氢化合物。 这些化合物可适用于治疗和/或预防性治疗疟疾。 此外，本发明提供了泛醌化合物和泛酸酰胺的组合。 将泛氢化合物与泛酸盐组合使抗疟药效力提高一个数量级。 假设抑制泛酰胺酶活性可以保护泛酸酰胺免受血清衍生的泛酰胺氨基酸酶的降解，从而揭示迄今未知的泛酰胺的抗疟疾活性。 因此，本发明首次使得可用的化合物和化合物的组合用于治疗和/或预防性治疗有需要的人或动物受试者中的疟疾感染，依赖于干扰宿主或病原体衍生的泛酰胺氨基酸酶依赖途径 。
-
公开(公告)号：WO2009013018A3
公开(公告)日：2009-01-29
申请号：PCT/EP2008/006182
申请日：2008-07-24
Applicant: STICHTING KATHOLIEKE UNIVERSITEIT RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTRE , DE VRIES, Ingrid, Jolanda, Monique , FIGDOR, Carl , BENITEZ RIBAS, Daniel
IPC: A61K39/00
Abstract: The invention relates to a method for providing an activated antigen-presenting cell or a composition that comprises at least one activated antigen-presenting cell, which method at least comprises the steps of providing a composition that comprises at least one antigen-presenting cell and contacting said composition with a vaccine. Suitably, the at least one dendritic cell is brought into a state in which it is capable of stimulating T-cells and/or a T-cell mediated response.
-
Patent Agency Ranking5.发明申请
公开(公告)号：WO2009013018A2
公开(公告)日：2009-01-29
申请号：PCT/EP2008/006182
申请日：2008-07-24
Applicant: STICHTING KATHOLIEKE UNIVERSITEIT RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTRE , DE VRIES, Ingrid, Jolanda, Monique , FIGDOR, Carl , BENITEZ RIBAS, Daniel
IPC: A61K39/00
CPC classification number: A61K39/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , Y10T29/49888
Abstract: The invention relates to a method for providing an activated antigen-presenting cell or a composition that comprises at least one activated antigen-presenting cell, which method at least comprises the steps of providing a composition that comprises at least one antigen-presenting cell and contacting said composition with a vaccine. Suitably, the at least one dendritic cell is brought into a state in which it is capable of stimulating T-cells and/or a T-cell mediated response.
Abstract translation: 本发明涉及一种用于提供活化的抗原呈递细胞或包含至少一种活化的抗原呈递细胞的组合物的方法，该方法至少包括以下步骤：提供包含至少一种抗原呈递细胞和接触的组合物 所述组合物用疫苗。 适当地，使至少一个树突状细胞处于其能够刺激T细胞和/或T细胞介导的应答的状态。
-
6.发明公开Method for deriving shape information of a person's dentition 审中-公开Verfahren zum Ableiten der Forminformation der Dentition einer Person
公开(公告)号：EP2368498A1
公开(公告)日：2011-09-28
申请号：EP10158059.5
申请日：2010-03-26
Applicant: Stichting voor de Technische Wetenschappen , Stichting Katholieke Universiteit, Radboud University Nijmegen Medical Centre
Inventor： Bergé, Stefaan Jozef , Kuijpers-Jagtman, Anne-Marie , Rangel, Frits , Maal, Thomas
CPC classification number: A61B6/14 , A61B6/466 , A61B6/5235 , A61B2090/3954 , A61C9/0053
Abstract: The present invention is related to a method for deriving shape information of a person's dentition. The method comprises the steps of
- obtaining a first data set by taking a 3D scan of the person's dentition with markers fixed in the person's intra-oral cavity,
- digitizing an impression of the person's dentition with the markers fixed, yielding a second data set,
- fusing the first and the second data set based on corresponding pairs of the markers,
- deriving the shape information from the fused first and second data sets.Abstract translation: 本发明涉及一种用于导出人牙列形状信息的方法。 该方法包括以下步骤：通过对固定在人的口腔内的标记进行人体牙列的3D扫描来获得第一数据集; - 使用固定的标记数字化人的牙列的印象，产生第二数据集 ， - 基于对应的标记对来融合第一和第二数据集， - 从融合的第一和第二数据集导出形状信息。
-
7.发明授权CONDITIONALLY IMMORTALIZED HUMAN PROXIMAL TUBULE CELL LINES EXPRESSING FUNCTIONAL INFLUX AND EFFLUX TRANSPORTERS 有权功能齐全，INFLUX- EXFLUXTRANSPORTER EXPRESSIERENDE，有条件的永生化人PROXIMALTUBULUS细胞系
公开(公告)号：EP2496687B1
公开(公告)日：2013-09-11
申请号：EP10776653.7
申请日：2010-11-04
Inventor： LEVTCHENKO, Elena Nikolaevna , VAN DEN HEUVEL, Lambertus Petrus Wilhelmus Johannes , WILMER, Martijn Jozef Gerardus , RUSSEL, Francois Gérard Marie
IPC: C12N5/071
CPC classification number: C12N5/0686 , C12N2510/04
-
8.发明授权
公开(公告)号：EP1516881B1
公开(公告)日：2010-06-30
申请号：EP04078220.3
申请日：2000-04-19
Inventor： Figdor, Carl Gustav , Geijtenbeek, Teunis Bernard Herman , Van Kooyk, Yvette , Torensma, Ruurd
IPC: C07K16/28 , A61K39/395
CPC classification number: C07K16/28 , A61K2039/505 , A61K2039/5154 , C07K16/2851 , C07K2317/73
Abstract: Use of a compound (I) that binds to a C-type lectin (II) on the surface of a dendritic cell (DC) for producing a composition for modulating (especially reducing) the immune response in an animal (particularly human or other mammal), provided that (II) is not the DEC-205 receptor. Independent claims are also included for the following: (1) an antibody (Ab), preferably monoclonal, directed against a C-type lectin (IIa) having a fully defined sequence of about 400 amino acids (given in the specification) or its natural variants, equivalents, parts, fragments or epitopes; (2) a pharmaceutical composition containing Ab and at least one carrier, excipient, adjuvant or auxiliary; (3) a combination of (I) attached to an antigen (Ag) or its fragment; (4) a method for producing, isolating and/or purifying DC from a biological sample or culture medium; and (5) DC prepared by method in (4). ACTIVITY : Immunosuppressant; immunostimulant; anti-allergic; antiviral; antitumor; antibacterial; antiprotozoal. MECHANISM OF ACTION : (I) mediates adhesion between DC and other cells by inhibiting interaction between (II) and (i) an ICAM (intracellular adhesion molecule) on T cells or (ii) gp 120 on HIV (human immune deficiency virus)-infected cells. A new (II), DC-SIGN, is not only involved in DC-T cell clumping but is also a major HIV receptor. Cells of the leukemia line K562 were transfected to express ICAM-3 and tested for binding to DC. Clumping between the cells was inhibited by antibodies directed against DC-SIGN, and DC-mediated T cell proliferation was then only about 1/3 of that in an antibody-free medium. The effect was greatly increased when anti-LFA3 antibodies were additionally present (practically no proliferation).
-
9.发明公开
公开(公告)号：EP2173374A2
公开(公告)日：2010-04-14
申请号：EP08785133.3
申请日：2008-07-24
IPC: A61K39/00
CPC classification number: A61K39/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , Y10T29/49888
Abstract: The invention relates to a method for providing an activated antigen-presenting cell or a composition that comprises at least one activated antigen-presenting cell, which method at least comprises the steps of providing a composition that comprises at least one antigen-presenting cell and contacting said composition with a vaccine. Suitably, the at least one dendritic cell is brought into a state in which it is capable of stimulating T-cells and/or a T-cell mediated response.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.027 seconds)
